AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.079

+0.0045.33%

Volume:50.40K

Turnover:4K

Market Cap:61.95M

PE:-4.49

High:0.080

Open:0.078

Low:0.078

Close:0.075

52wk High:0.165

52wk Low:0.053

Shares:784.22M

Float Shares:351.37M

Volume Ratio:0.04

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:4.87

PE(LYR):-4.49

Loading ...

Overview Company News Filings

Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study

THOMSON REUTERS

Neurizon appoints Ross Murdoch independent non-executive director

Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase

THOMSON REUTERS

Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million

Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln

THOMSON REUTERS

Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln

THOMSON REUTERS

Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial

Neurizon says NUZ-001 preclinical data supports multi-pathway protein clearance in ALS models

Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%

MT Newswires Live

Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed

THOMSON REUTERS

Neurizon Therapeutics - Michael Thurn Resigns as Managing Director and CEO

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.079,"timestamp":1789539120000,"preClose":0.075,"halted":0,"volume":50398,"delay":0,"changeRate":0.053333333333333385,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"Not Yet Opened","change":0.004,"latestTime":"09-16 16:12:00 AEST","open":0.078,"high":0.08,"low":0.078,"amount":3937,"amplitude":0.026667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.075,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.0419998943350061,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.075,"auctionPrice":0.075,"auctionVolume":40000,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452615853}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":0.0419998943350061,"shares":784215600,"dividePrice":0,"high":0.08,"amplitude":0.026667,"preClose":0.075,"low":0.078,"week52Low":0.053,"pbRate":"4.87","psRate":"3.52","week52High":0.165,"institutionHeld":0,"latestPrice":0.079,"eps":-0.0176,"divideRate":0,"volume":50398,"delay":0,"ttmEps":-0.0176,"open":0.078,"prevYearClose":0.085,"prevWeekClose":0.076,"prevMonthClose":0.056,"prevQuarterClose":0.06,"fiveDayClose":0.085,"twentyDayClose":0.06,"sixtyDayClose":0.06,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635296162","title":"Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296162?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:20","pubTimestamp":1778628007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634389422","title":"Neurizon appoints Ross Murdoch independent non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2634389422","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634389422?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:32","pubTimestamp":1778455925,"startTime":"0","endTime":"0","summary":"Neurizon appointed Ross Murdoch as independent non-executive director, effective immediately, as it advances NUZ-001 in the HEALEY ALS Platform Trial.Murdoch brings more than 30 years of pharmaceutical and biotech leadership, including senior roles at AstraZeneca, GlaxoSmithKline, Shire Pharmaceuticals; currently CEO and president of Extractas Bioscience.Michael Thurn retired from board, effective immediately, following previously announced transition from managing director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDLxhXrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109981661.USD","BK7096","LU0058720904.USD","SG9999013999.USD","LU1015430645.USD","LU0211331839.USD","SGXZ57979304.SGD","NUZ.AU","SG9999001176.USD","LU0971552830.HKD","LU0306807586.USD","LU0203347892.USD","LU0306806265.USD","LU1035777561.USD","LU0575583348.USD","LU1302929846.USD","LU0225284248.USD","LU1202635105.USD","LU1481599808.USD","IE00BQJZX424.USD","LU0203345920.USD","LU2646069778.SGD","LU0289739699.SGD","LU0987226296.USD","LU1400636657.SGD","LU0161305163.EUR","LU0985481810.HKD","LU1228905037.USD","LU1487256676.USD","LU0557290698.USD","LU2468319806.SGD","LU0971552673.USD","LU0321505439.SGD","LU0225283273.USD","LU1064927863.SGD","LU0545562505.USD","LU0321505868.SGD","LU1983299246.USD","LU0225771236.USD","IE00BWDBJ516.SGD","GSK.UK","LU1046248800.SGD","IE0034235071.USD","BK5011","IE00B3T34201.USD","LU1400636574.HKD","LU2089984988.USD","SG9999001176.SGD","LU1481600234.SGD","LU1098665638.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633054691","title":"Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2633054691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633054691?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:06","pubTimestamp":1778195187,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUECH3XD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557317","title":"Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631557317?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:38","pubTimestamp":1777505905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE3FTPKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627225246","title":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627225246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627225246?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:42","pubTimestamp":1776303766,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 MillionApril 16  - Neurizon Therapeutics Ltd NUZ.AX:ANNOUNCES PLACEMENT OF ENTITLEMENT OFFER SHORTFALL TO RAISE ~A$2.7 MILLIONTOTAL AMOUNT TO BE RAISED UNDER ENTITLEMENT OFFER IS ~A$8.5 MILLIONFurther company coverage: NUZ.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627147256","title":"Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627147256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627147256?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627025614","title":"Neurizon Therapeutics Ltd - Total Amount to Be Raised Under Entitlement Offer Is ~a$8.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627025614?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626716701","title":"Neurizon publishes investor deck outlining NUZ-001 ALS program in HEALEY platform trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2626716701","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626716701?lang=en_us&edition=fundamental","pubTime":"2026-04-10 16:01","pubTimestamp":1775808083,"startTime":"0","endTime":"0","summary":"Neurizon outlined progress for lead asset NUZ-001, an oral small molecule being advanced in ALS through Regimen I of HEALEY ALS Platform Trial.Trial timeline targets enrollment completion in Q3-Q4 2026, with topline data expected in Q3 2027.Neurizon flagged supply-chain de-risking via Elanco, with commercial supply agreement execution expected in Q2 2026 and API supply secured to end of HEALEY trial.Cash at Mar. 31, 2026 was AUD 16.7 million, with convertible note debt of AUD 5.6 million, implying net cash of AUD 11.1 million.Capital structure snapshot listed 708,878,681 shares outstanding, with market capitalization of AUD 60.3 million and enterprise value of AUD 49.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL2XkZvJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624150551","title":"Neurizon says NUZ-001 preclinical data supports multi-pathway protein clearance in ALS models","url":"https://stock-news.laohu8.com/highlight/detail?id=2624150551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624150551?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:19","pubTimestamp":1774999173,"startTime":"0","endTime":"0","summary":"Neurizon reported new preclinical results on April 1, 2026, outlining additional evidence on NUZ-001 biological activity.Data showed NUZ-001 increased multiple protein-clearance processes in human neuronal models, supporting a multi-pathway approach to neurodegenerative disease.Findings strengthened rationale for NUZ-001 development in ALS, where impaired protein clearance is linked to neuronal damage.Neurizon positioned results as supportive of ongoing clinical evaluation of NUZ-001 in HEALEY ALS Platform Trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLMHnYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484594","title":"Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484594","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484594?lang=en_us&edition=fundamental","pubTime":"2026-03-16 08:40","pubTimestamp":1773621622,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.The company's shares fell 13% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NUZ.AU","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619748557","title":"Neurizon Therapeutics - Sergio Duchini to Assume Role of Executive Chair Until New CEO Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619748557","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619748557?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619572485","title":"Neurizon Therapeutics  - Michael Thurn Resigns as Managing Director and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2619572485","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619572485?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:20","pubTimestamp":1773609614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}